Home · Client updates · Excessive Prices
The Israeli Competition Director General fined MBI and company officers after they spiked the price of a life-saving drug called Leadiant by hundreds of percentage points.
Israeli district courts have already recognized the possibility of suing a monopoly for charging an unfair excessive price, but the Israeli Supreme Court’s recognition of this cause of action ends defendants’ potential arguments for opposing this very possibility.